#Paris #France #Molecular Diagnostics #Seegene

Seegene Expands Its European Presence with New French Subsidiary

Seegene, Inc., a prominent player in the field of molecular diagnostics, has officially announced the establishment of a new subsidiary in France. This strategic move marks Seegene's commitment to reinforcing its foothold in the European market, following similar expansions in Italy and Germany. With France being recognized as the second-largest market for molecular diagnostics in Europe, this subsidiary is designed to meet increasing demand for innovative healthcare solutions, particularly in the areas of sexually transmitted infections (STIs), gastrointestinal infections, and respiratory virus testing.

According to insights from Grand View Research, France's market is estimated to reach around EUR 600 million, representing approximately 15% of Europe's overall diagnostics market. The country's healthcare landscape is experiencing a surge in demand for sophisticated diagnostic tools, and Seegene aims to cater to this need through its latest offerings. The new subsidiary will bolster local operations by enhancing customer support and market development, enabling closer collaboration with healthcare stakeholders across the region.

Daniel Shin, Seegene's Executive Vice President and Chief Global Sales and Marketing Officer, emphasized the significance of rapid product delivery and laboratory efficiency as key competitive factors in France's divided private-public healthcare system. He stated, "The subsidiary will enable Seegene to gain a better understanding of the French healthcare landscape, strengthening local customer service while promoting growth in our in vitro diagnostics business through dedicated expertise."

One of the subsidiary's core objectives is to accelerate the adoption of Seegene's groundbreaking solutions, including the CURECA™ system, a fully automated and unmanned PCR diagnostics unit, and STAgora™, a platform for real-time data analytics and predictive insights for diagnostic procedures. These innovations have the potential to significantly enhance the efficiency and reliability of disease detection and management, thereby improving patient outcomes.

As part of its expansion strategy, bringing the French subsidiary into the fold elevates Seegene's tally of overseas sales subsidiaries to nine, supported by an extensive distribution network that spans 94 countries. Notably, overseas sales accounted for approximately 93% of Seegene's total revenue in the first half of 2025, with 63% of these sales sourced from the European market. The continued growth in this region is pivotal to Seegene's long-term global expansion roadmap.

Seegene's advanced syndromic real-time PCR technology has earned its reputation during critical times, particularly during the recent COVID-19 pandemic when it provided more than 340 million COVID-19 tests across over 100 countries. The company’s dedication to innovation and excellence positions it well for future developments in molecular diagnostics.

As Seegene moves forward with its new French operations, industry stakeholders and customers alike will be eager to see how this initiative will enhance diagnostic access and drive healthcare advancements across Europe. For further information and updates on Seegene's progress and offerings, visit Seegene.com or follow them on LinkedIn.